OKYO Pharma CFO discloses share and option holdings

OKYO Pharma Ltd’s chief financial officer, Keeren Rameshchandra Shah, reports his existing equity stake in the company.

Accepted by SEC EDGAR 05/22/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Ltd’s chief financial officer, Keeren Rameshchandra Shah, reports his existing equity stake in the company. He holds 16,667 shares of common stock directly. The filing also lists multiple option awards over common stock, including grants for 31,250 shares at a 1.50 exercise price expiring in 2035 and 25,193 shares at a 2.13 exercise price expiring in 2033.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Shah Keeren Rameshchandra

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	Options	--	--	--
Holding	COMMON STOCK	--	--	--

Holdings: Options — 504,819 contracts (Direct); COMMON STOCK — 16,667 shares (Direct)

Key Figures

Direct common shares: 16,667 shares Option grant A: 31,250 underlying shares at 1.50 Option grant B: 21,667 underlying shares at 1.46 +2 more

5 metrics

Direct common shares 16,667 shares Total common stock held directly by CFO after reported holdings

Option grant A 31,250 underlying shares at 1.50 Options over common stock expiring 2035-03-25

Option grant B 21,667 underlying shares at 1.46 Options over common stock expiring 2034-03-13

Option grant C 21,250 underlying shares at 1.57 Options over common stock expiring 2033-10-20

Option grant D 25,193 underlying shares at 2.13 Options over common stock expiring 2033-03-14

Key Terms

Options, exercise price, expiration date, underlying security shares

4 terms

Options financial

"security_title: "Options" with underlying common stock and exercise prices"

Options are contracts that give investors the right to buy or sell an asset at a specific price within a certain time frame. They function like a reservation or a ticket that allows for potential profit or protection against price changes, making them useful tools for managing investment risks or speculating on market movements.

exercise price financial

"conversion_or_exercise_price fields such as "1.5000" and "2.1300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date fields such as "2035-03-25T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security shares financial

"underlying_security_shares values like "31250.0000" and "25193.0000""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does OKYO Pharma (OKYO) disclose about its CFO’s share ownership?

The chief financial officer, Keeren Rameshchandra Shah, reports direct ownership of 16,667 OKYO Pharma common shares. This disclosure outlines his existing equity stake rather than new market transactions, helping investors understand management’s current alignment with shareholders.

How many OKYO Pharma (OKYO) common shares does the CFO hold directly?

The CFO holds 16,667 shares of OKYO Pharma common stock directly. This figure comes from the reported total_shares_following_transaction field for common stock and reflects his current direct ownership position in the company’s equity.

What stock options in OKYO Pharma (OKYO) does the CFO report?

The CFO reports several option grants over OKYO Pharma common stock, including tranches for 31,250 underlying shares at a 1.50 exercise price expiring in 2035. Additional grants cover tens of thousands of shares with exercise prices between 1.46 and 2.13 and expirations through 2035.

What are examples of strike prices and expirations for OKYO Pharma (OKYO) CFO options?

Reported options include underlying shares at a 1.50 exercise price expiring on 2035-03-25 and at a 2.13 exercise price expiring on 2033-03-14. Other awards use exercise prices of 1.46 and 1.57, generally expiring between 2033 and 2035.

Does the OKYO Pharma (OKYO) CFO filing show any recent share purchases or sales?

The disclosure classifies all entries as holdings with unknown transaction codes, and summary data show zero buys and zero sells. It therefore functions as a snapshot of existing ownership and option positions, not as a record of new open-market trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shah Keeren Rameshchandra

(Last) (First) (Middle)

C/O OKYO PHARMALTD,

14-15 CONDUIT STREET

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK	16,667	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	03/14/2024	03/14/2033	common stock	25,192	$2.13	D
Options	03/14/2025	03/14/2033	common stock	25,192	$2.13	D
Options	03/14/2026	03/14/2033	common stock	25,193	$2.13	D
Options	03/14/2027	03/14/2033	common stock	25,193	$2.13	D
Options	10/20/2024	10/20/2033	common stock	21,250	$1.57	D
Options	10/20/2025	10/20/2033	common stock	21,250	$1.57	D
Options	10/20/2026	10/20/2033	common stock	21,250	$1.57	D
Options	10/20/2027	10/20/2033	common stock	21,250	$1.57	D
Options	03/13/2025	03/13/2034	common stock	21,666	$1.46	D
Options	03/13/2026	03/13/2034	common stock	21,667	$1.46	D
Options	03/13/2027	03/13/2034	common stock	21,667	$1.46	D
Options	04/03/2026	10/03/2034	common stock	31,250	$1.5	D
Options	10/03/2026	10/03/2034	common stock	31,250	$1.5	D
Options	10/03/2027	10/03/2034	common stock	31,250	$1.5	D
Options	10/03/2028	10/03/2034	common stock	31,250	$1.5	D
Options	01/29/2026	01/29/2035	common stock	180	$1.6	D
Options	01/29/2027	01/29/2035	common stock	180	$1.6	D
Options	01/29/2028	01/29/2035	common stock	181	$1.6	D
Options	01/29/2026	01/29/2035	common stock	877	$1.6	D
Options	01/29/2027	01/29/2035	common stock	877	$1.6	D
Options	01/29/2028	01/29/2035	common stock	877	$1.6	D
Options	01/29/2029	01/29/2035	common stock	877	$1.6	D
Options	03/25/2026	03/25/2035	common stock	31,250	$1.5	D
Options	03/25/2027	03/25/2035	common stock	31,250	$1.5	D
Options	03/25/2028	03/25/2035	common stock	31,250	$1.5	D
Options	03/25/2029	03/25/2035	common stock	31,250	$1.5	D

Explanation of Responses:

	/s/ Keeren Shah	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)